Market Alert: US Sets Tariff Floor at 15% – Potentially Rising to 50% from 01 August 2025
ReNerve Limited (ASX: RNV) has delivered strong Q4 FY25 results, with annual revenue up 53% year-over-year and quarterly revenue up 25%, ending the period with $4.75 million in cash . The company expanded its global footprint through a strategic partnership with Berkeley Biologics LLC, adding dermal and amniotic tissue products to its U.S. distribution network, with launches expected by Q3 CY25. ReNerve also signed a partnership with NetCentrix Ventures to access India’s US$115 million nerve repair market, while achieving regulatory approval for its NervAlign® Nerve Cuff in Bahrain, marking entry into the MENA region. Operational highlights include ongoing development of the NervAlign® Nerve Conduit, targeted for market entry by Q4 CY25. Supported by a growing international presence, high-margin innovative products, and a strong cash position, ReNerve is well-positioned to accelerate commercialisation and expand into new high-growth markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Jul 30, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
